Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

JAMA Oncology

Volumn 4, Issue 2, 2018, Pages 157-158

  Prasad, Vinay ^a,b   Kaestner, Victoria ^a   Mailankody, Sham ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; B RAF KINASE; DOCETAXEL; ENZALUTAMIDE; LAROTRECTINIB; PEMBROLIZUMAB; PHOSPHOTRANSFERASE; TROPOMYOSIN RECEPTOR KINASE; TUMOR MARKER; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANAPLASTIC THYROID CARCINOMA; ANTIGEN EXPRESSION; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CLASSIFICATION; CANCER MORTALITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENE FUSION; GENE MUTATION; HAIRY CELL LEUKEMIA; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATIONAL LOAD; MYELOMA; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; POSTMARKETING SURVEILLANCE; PROSTATE CANCER; SHORT SURVEY; SOLID MALIGNANT NEOPLASM; TREATMENT RESPONSE; TROPOMYOSIN RECEPTOR KINASE GENE; UNITED STATES; BRAIN TUMOR; COLORECTAL TUMOR; COMPLICATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HEREDITARY TUMOR SYNDROME; NEOPLASM; PATHOLOGY; PROCEDURES; PROGNOSIS; STANDARDS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; PROGNOSIS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85045592392     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.4182     Document Type: Short Survey

References (9)

1. @adamfeuerstein. How soon before we no longer refer to breast, lung, colon cancer, but instead only describe genetic makeup of cancer? Is that possible? May 23, 2017. https://twitter.com/adamfeuerstein/status/867095289127153664 ?lang=en. Accessed November 3, 2017.
2. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. Abstract LBA2501. 2017 ASCO Annual Meeting; Chicago IL. June 3, 2017.
3. Merck & Co. Highlights of Prescribing Information: KEYTRUDA. https://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pd. Accessed November 3, 2017.
4. Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373(18):1733-1747.
5. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
6. HymanDM,PuzanovI,SubbiahV,etal.Vemurafenib in multiple nonmelanoma cancers with BRAFV600 mutations.NEngl J Med. 2015;373(8):726-736.
7. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.
8. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
9. American Cancer Society. Cancer Facts and Figures, 2017. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Accessed November 3, 2017.